Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • NPPA revises ceiling...

    NPPA revises ceiling prices of 5 scheduled drug formulations

    Written by Ruby Khatun Khatun Published On 2017-05-16T13:10:10+05:30  |  Updated On 16 May 2017 1:10 PM IST
    NPPA revises ceiling prices of 5 scheduled drug formulations

    New Delhi: Drug price regulator NPPA revised ceiling prices of five scheduled drug formulations used in treatment of various ailments, including seizures, epilepsy and allergic rhinitis, among others.


    In a notification, the National Pharmaceutical Pricing Authority (NPPA) said it has revised the prices of phenobarbitone tablet 30mg, sodium valproate tablet 200mg, pheniramine injection 22.75 mg/ml of 2 ml pack, pheniramine injection 22.75 mg/ml of 10 ml pack and adrenaline injection of 1mg/ml.























































    Sl. No.Name of the Scheduled FormulationDosage form & StrengthUnitCeiling Price (Rs.)
    (1)(2)(3)(4)(5)
    1.PhenobarbitoneTablet 30mg1 Tablet1.16
    2.Sodium ValproateTablet 200mg1 Tablet2.93
    3.PheniramineInjection 22.75 mg/ml (2 ML Pack)1 ML1.44
    4.PheniramineInjection 22.75 mg/ml (10 ML Pack)1 ML1.06
    5.AdrenalineInjection 1mg/ml1 ML14.81

    The NPPA fixes ceiling price of essential medicines of Schedule I under the Drugs (Prices Control) Order (DPCO) 2013.


    The government had notified DPCO 2013, which covers 680 formulations, with effect from May 15, 2014, replacing the 1995 order that regulated prices of only 74 bulk drugs.

    Set up in 1997, NPPA has been entrusted with the task of fixing and revising prices of pharma products, enforcement of provisions of DPCO and monitoring the prices of controlled and decontrolled drugs.
    adrenaline injectionallergic rhinitisceiling pricesDPCODrugs Prices Control OrderEpilepsyNational Pharmaceutical Pricing AuthorityNPPApheniramine injectionphenobarbitone tabletscheduled drug formulationsseizuressodium valproate tablet
    Source : PTI inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok